Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes

MET exon 14 skipping mutations in non–small-cell lung cancer are important biomarkers for targeted therapy, making accurate detection essential. This study analyzed 379 non–small-cell lung cancers with mutations in MET exon 14 and adjacent splice sites using DNA- and RNA-based next-generation sequencing (NGS). The 379 samples contained 171 distinct mutations around MET exon 14, highlighting the diversity of these mutations. A total of 114 mutations were analyzed with both a DNA- and an RNA-based NGS assay.